Revenue: As of FY2025, the actual value is USD 1.037 B, beating the estimate of USD 1.033 B.EPS: As of FY2025, the actual value is USD 4.75, beating the estimate of USD 4.7133.EBIT: As of FY2025, the actual value is USD 219.55 M.<h4>Consolidated Financial Performance</h4>Balchem Corporation’s total net sales increased by 8.8% to $1,037,161 in 2025 from $953,684 in 2024. Gross margin rose by 10.2% to $370,633 in 2025 from $336,206 in 2024, with gross margin as a percentage of net sales reaching 35.7% in 2025, up from 35.3% in 2024. Operating expenses increased by 5.2% to $161,307 in 2025 from $153,297 in 2024, primarily due to higher compensation-related expenses and professional services, partially offset by lower amortization and reduced agent and broker commissions. Earnings from operations grew by 14.4% to $209,326 in 2025 from $182,909 in 2024, resulting in an operating margin of 20.2% in 2025, compared to 19.2% in 2024. Net earnings increased by 20.5% to $154,845 in 2025 from $128,475 in 2024.<h4>Segmented Net Sales</h4>Net sales for the Human Nutrition and Health (HNH) segment increased by 9.9% to $659,387 in 2025 from $600,258 in 2024, driven by volume and mix, average selling prices, and foreign currency exchange rates. The Animal Nutrition and Health (ANH) segment’s net sales increased by 7.5% to $230,852 in 2025 from $214,710 in 2024, attributed to average selling prices, volume and mix, and foreign currency exchange rates. Specialty Products (SP) net sales grew by 6.2% to $140,976 in 2025 from $132,749 in 2024, due to average selling prices, foreign currency exchange rates, and volume and mix. Other and Unallocated net sales saw a slight decrease of 0.4% to $5,946 in 2025 from $5,967 in 2024.<h4>Segmented Earnings from Operations</h4>Earnings from operations for the Human Nutrition and Health (HNH) segment increased by 13.2% to $153,906 in 2025 from $135,957 in 2024, primarily due to gross margin contribution, partially offset by increased operating expenses. The Animal Nutrition and Health (ANH) segment’s earnings from operations increased by 33.4% to $18,687 in 2025 from $14,013 in 2024, mainly driven by gross margin contribution, partially offset by higher operating expenses. Specialty Products (SP) earnings from operations increased by 7.5% to $42,901 in 2025 from $39,906 in 2024, due to gross margin contribution, partially offset by increased operating expenses. Other and Unallocated earnings from operations improved to -$6,168 in 2025 from -$6,967 in 2024.<h4>Cash Flow</h4>Cash flows provided by operating activities increased by 19.0% to $216,556 in 2025 from $181,999 in 2024, primarily due to higher net earnings and changes in working capital. Cash flows used in investing activities decreased by 26.5% to -$43,891 in 2025 from -$59,736 in 2024, which included capital expenditures and intangible assets acquired totaling $43,489 in 2025 compared to $35,661 in 2024. Cash flows used in financing activities increased by 14.2% to -$152,810 in 2025 from -$133,815 in 2024, mainly due to higher share repurchases.<h4>Outlook/Guidance</h4>Balchem Corporation projects capital expenditures to range from $40,000 to $45,000 for 2026, including continued investments in energy and water-saving projects and exploration of additional renewable energy opportunities. The company expects its operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. Balchem Corporation is also actively pursuing additional acquisition candidates and may seek additional bank loans or access to financial markets to fund acquisitions, operations, or other cash requirements.

Balchem | 10-K: FY2025 Revenue Beats Estimate at USD 1.037 B